Nicox SA announced NDA submissions for NCX 470 expected in 2026 in the U.S. and China. The company believes it can finance operations for at least 12 months and expects to repay existing financial debts in 2026. Recent licensing payments position the company well for future growth opportunities.

Financial results for the first half of 2025 show revenue of €1.5 million, with operating expenses at €6.8 million and a net loss of €8.9 million. Cash and cash equivalents were at €5.7 million as of June 30, 2025. Nicox SA remains committed to cost control and resource optimization for strategic objectives.

Key future milestones include NCX 470 NDA submission in the U.S. expected in H1 2026, followed shortly by submission in China. The Phase 3 clinical program for NCX 470 in Japan was initiated in summer 2025, managed and financed by Kowa. License payments totaling €12.5 million were received in August and September 2025.

Read more at GlobeNewswire: Nicox Provides First Half 2025 Financial Results